Omnicell, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 01, 2023 at 04:01 pm EDT
Share
Omnicell, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 298.97 million compared to USD 331.39 million a year ago. Net income was USD 3.45 million compared to USD 9.07 million a year ago. Basic earnings per share from continuing operations was USD 0.08 compared to USD 0.21 a year ago. Diluted earnings per share from continuing operations was USD 0.08 compared to USD 0.2 a year ago.
For the six months, revenue was USD 589.6 million compared to USD 650.21 million a year ago. Net loss was USD 11.55 million compared to net income of USD 17.28 million a year ago. Basic loss per share from continuing operations was USD 0.26 compared to basic earnings per share from continuing operations of USD 0.39 a year ago. Diluted loss per share from continuing operations was USD 0.26 compared to diluted earnings per share from continuing operations of USD 0.37 a year ago.
Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Companyâs XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.
OMNICELL, INC. 
